Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye injection aims to slow vision loss from Age-Related macular degeneration

NCT ID NCT06970665

Ongoing Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 months. The main goal is to see if the treatment is safe and well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
avacincaptad pegol (ASP3021, IZERVAY)
What this could lead to
If successful, this could confirm that ASP3021 is safe for Japanese patients with geographic atrophy, potentially slowing vision loss.
What could go wrong
This is a small, single-arm safety study with only 20 participants, so results may not apply broadly. Side effects from eye injections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION GEOGRAPHIC ATROPHY

Contacts and locations

Locations

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, Japan

  • Jichi Medical University Hospital

    Shimotsuke-shi, Tochigi, Japan

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, Japan

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Nihon University Hospital

    Chiyoda-ku, Tokyo, Japan

  • Seirei Hamamatsu General Hospital

    Hamamatsu, Shizuoka, Japan

  • The University of Osaka Hospital

    Suita-shi, Osaka, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Toyama University Hospital

    Toyama, Toyama, Japan

  • University Of Yamanashi Hospital

    Chuo-shi, Yamanashi, Japan

  • University of the Ryukyus hospital

    Ginowan-shi, Okinawa, Japan

  • Yokohama City University Medical Center

    Yokohama, Kanagawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.